Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD

Inflammatory Bowel Diseases

Volumn 23, Issue 8, 2017, Pages 1382-1393

  Yoon, Soon Man ^a,b   Haritunians, Talin ^a   Chhina, Sultan ^a   Liu, Zhenqiu ^a   Yang, Shaohong ^a   Landers, Carol ^a   Li, Dalin ^a   Ye, Byong Duk ^a,c   Shih, David ^a   Vasiliauskas, Eric A ^a   Ippoliti, Andrew ^a   Rabizadeh, Shervin ^a   Targan, Stephan R ^a   Melmed, Gil Y ^a   McGovern, Dermot P B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Chungbuk National University Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

anti TNF; Crohn's disease; response; ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; TUMOR NECROSIS FACTOR INHIBITOR; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; COLON; DRUG EFFECT; FOLLOW UP; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; COLON; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GENETIC MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85026483867     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000001150     Document Type: Article

References (70)

1. Van Assche G, Rutgeerts P. Anti-TNF agents in Crohn's disease. Expert Opin Investig Drugs. 2000;9:103-111.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
4. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther. 2014;39:1349-1362.
5. Dignass A, Van Assche G, Lindsay JO, et al. The second european evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4: 28-62.
6. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
7. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
8. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33: 987-995.
9. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545.
10. Lowenberg M, D'Haens G. Next-generation therapeutics for IBD. Curr Gastroenterol Rep. 2015;17:21.
11. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
12. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
13. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
14. Grove ML, Yu B, Cochran BJ, et al. Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS One. 2013;8: e68095.
15. Barber GE, Yajnik V, Khalili H, et al. Genetic markers predict primary non-response and durable response to anti-TNF biologic therapies in Crohn's disease. Am J Gastroenterol. 2016;111:1816-1822.
16. Orlando A, Colombo E, Kohn A, et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005;37:577-583.
17. Therneau T. A Package for Survival Analysis in S. 2015. Available at: https://CRAN.R-project.org/package=survival. Accessed May 2017.
18. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available at: https://www.R-project.org/. Accessed May 2017.
19. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575.
20. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156-167.
21. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979-986.
22. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
23. Matthews L, Gopinath G, Gillespie M, et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 2009;37: D619-D622.
24. Peri S, Navarro JD, Kristiansen TZ, et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004;32: D497-D501.
25. Schaefer CF, Anthony K, Krupa S, et al. PID: the pathway interaction database. Nucleic Acids Res. 2009;37:D674-D679.
26. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: proteinprotein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41:D808-D815.
27. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016; 10:989-997.
28. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659.
29. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15-29.
30. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
31. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468.
32. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.
33. Siegel CA, Melmed GY. Predicting response to Anti-TNF agents for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2009;2: 245-251.
34. Kapel N, Meillet D, Favennec L, et al. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis. Eur J Clin Chem Clin Biochem. 1992;30:197-202.
35. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
36. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350-355.
37. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, et al. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007;13:1561-1566.
38. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110:1810-1819.
39. Jurgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105: 1811-1819.
40. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355.
41. Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict longterm outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531-538.
42. Li D, Silverberg MS, Haritunians T, et al. TNFRSF1B is associated with ANCA in IBD. Inflamm Bowel Dis. 2016;22:1346-1352.
43. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71: 431-436.
44. Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13:2233-2240.
45. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
46. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
47. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.
48. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
49. Matsukura H, Ikeda S, Yoshimura N, et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther. 2008;27:765-770.
50. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010;16: 1357-1366.
51. Hlavaty T, Ferrante M, Henckaerts L, et al. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis. 2007;13:372-379.
52. Medrano LM, Taxonera C, Marquez A, et al. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. Hum Immunol. 2014;75:71-75.
53. Medrano LM, Taxonera C, Gonzalez-Artacho C, et al. Response to infliximab in Crohn's disease: genetic analysis supporting expression profile. Mediators Inflamm. 2015;2015:318207.
54. Li W, Zhang Q, Oiso N, et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet. 2003;35: 84-89.
55. Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46: 310-315.
56. Halloran B, Chang J, Shih DQ, et al. Molecular patterns in human ulcerative colitis and correlation with response to infliximab. Inflamm Bowel Dis. 2014;20:2353-2363.
57. Lee JC, Lyons PA, McKinney EF, et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011;121:4170-4179.
58. Koifman E, Karban A, Mazor Y, et al. Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factors. Inflamm Bowel Dis. 2013;19:1639-1644.
59. Fattouh R, Guo CH, Lam GY, et al. Rac2-deficiency leads to exacerbated and protracted colitis in response to Citrobacter rodentium infection. PLoS One. 2013;8:e61629.
60. Muise AM, Xu W, Guo CH, et al. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut. 2012;61:1028-1035.
61. Nauseef WM. Biological roles for the NOX family NADPH oxidases. J Biol Chem. 2008;283:16961-16965.
62. Resh MD. Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol. 1998;30:1159-1162.
63. Elias D, Vever H, Laenkholm AV, et al. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene. 2015;34:1919-1927.
64. Grosso S, Puissant A, Dufies M, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther. 2009;8:1924-1933.
65. Takahashi T, Serada S, Ako M, et al. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer. 2013;133:2737-2743.
66. Lopes F, Wang A, Smyth D, et al. The Src kinase Fyn is protective in acute chemical-induced colitis and promotes recovery from disease. J Leukoc Biol. 2015;97:1089-1099.
67. Manczinger M, Kemeny L. Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach. PLoS One. 2013;8:e80751.
68. Jang H, Kim HJ, Kim DH, et al. Small heterodimer partner-interacting leucine zipper protein inhibits adipogenesis by regulating peroxisome proliferator-activated receptor gamma activity. Life Sci. 2015;132:49-54.
69. Moran GW, Dubeau MF, Kaplan GG, et al. The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings timetrend analysis. Inflamm Bowel Dis. 2013;19:2949-2956.
70. Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238-1243.